MKI67 and breast carcinoma: These findings were subsequently validated in a detailed analysis of 498 early breast cancer patients, in which we compared good and poor prognosis ‘LA’ and ‘LB’ IHC signatures, which included Ki-67 and p53 in addition to ER, PR and HER2.